Frontier Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Frontier Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,591	Closed	-$1.52M	–	270
2023 Q2	$1.52M	Buy	+6,591	New	+$1.79M	0.01%	252
2020 Q4	–	Sell	-27,299	Closed	-$3.24M	–	289
2020 Q3	$3.24M	Sell	27,299 -44,615	-62%	-$4.84M	0.03%	276
2020 Q2	$8.14M	Sell	71,914 -20,998	-23%	-$2.06M	0.07%	234
2020 Q1	$6.2M	Buy	92,912 +38,712	+71%	+$3.23M	0.07%	224
2019 Q4	$4.94M	Buy	54,200 +32,718	+152%	+$3.17M	0.04%	252
2019 Q3	$1.85M	Sell	21,482 -5,993	-22%	-$562K	0.01%	273
2019 Q2	$2.88M	Sell	27,475 -60,228	-69%	-$6.45M	0.02%	276
2019 Q1	$11M	Buy	87,703 +3,835	+5%	+$477K	0.08%	230
2018 Q4	$9.45M	Buy	+83,868	New	+$13M	0.08%	236

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Frontier Capital Management's MDGL Position: Q3 2023 in Review

Frontier Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 6,591 shares — an estimated $1.52M sold.

Frontier Capital Management first reported a position in MDGL in Q4 2018 and held it in 9 quarters. The position peaked at $11M in Q1 2019. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

Frontier Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Frontier Capital Management sold 6,591 Madrigal Pharmaceuticals shares in Q3 2023, an estimated $1.52M.
Frontier Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 9 quarters.
Frontier Capital Management's Madrigal Pharmaceuticals position peaked at $11M in Q1 2019.
205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on Frontier Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.